Infection Control Market Segment Analysis By Type, End-Use, Region And Forecast Till 2030: Grand View Research Inc.

San Francisco, 13 Dec 2023: The Report Infection Control Market Size, Share & Trends Analysis Report By Type (Equipment, Services, Consumables), By End-use (Hospitals, Medical Device Companies, Clinical Laboratories, Pharmaceutical Companies, Others), By Region, And Segment Forecasts, 2023 – 2030

The global infection control market size is expected to reach USD 359.6 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 6.7% from 2023 to 2030. The market is driven by rising concerns with respect to a significant upsurge in hospital-acquired infections globally. This is believed to facilitate greater penetration of infection control products. An influx in the development of new biologics and subsequent demand for sterilized formulations serve as key growth factors for the overall market. Healthcare organizations are focused on implementing strategies for early recognition, reporting, isolation, and surveillance of disease episodes of potential public health concern.

In addition, an increasing number of intensive training modules, for nurses and other medical staff, on infection prevention and control is presumed to provide high potential for extensive usage of infection control products over the coming years. For instance, College of Nurses of Ontario released guidelines concerning standard practices, that is focused on maintaining hand hygiene to reduce contamination and spread of infection. Furthermore, Centers for Disease Control and Prevention (CDC) has released guidelines for disinfection and sterilization for efficient usage of infection control products by healthcare personnel in a wide array of healthcare settings such as ambulatory care, home care, hospitals, and others.

As a consequence of the aforementioned factors, it is presumed that there will be a significant improvement in the overall penetration rate of infection prevention and control products, which is also anticipated to fuel the market demand as well as the revenue to unprecedented heights. The demand for infection control also stemmed from the need to stop the spread of COVID-19. Governments’ authorities prescribed guidelines and policies to safeguard public health and prevent cross-contamination. The CDC, and the U.S. Department of Health and Human Services, provide an extensive library of guidelines on basic infection control and prevention, device-associated infections, antibiotic resistance, disease / organism-specific infection, and procedure-associated infections to promote the control of hospital-acquired infections.

Increase in strategic initiatives undertaken by companies including include strategic partnerships, mergers and acquisitions, and product development are further propelling the market growth. For instance, Getinge expanded its partnership with XPO Logistics under which the latter will provide warehousing and transport services from the Netherlands to the EMEA region for the company’s infection control business unit in February 2021.

Access Research Report of Infection Control Market @ https://www.grandviewresearch.com/industry-analysis/infection-control-market

Infection Control Market Report Highlights

• Services are predicted to observe exponential growth as a consequence of the increasing presence of third-party reprocessors and outsourcing of sterilization as a result of associated cost-efficiency
• Hospitals accounted for a substantial share in 2022, as a consequence of high clinical urgency to curb the growing incidence of hospital-acquired infections
• North America captured a dominant share of the overall market as of 2022 owing to extensive infection prevention activities being implemented in hospitals, medical device,s and pharmaceutical companies
• The market in Asia Pacific is projected to witness exponential growth during the forecast period as a result of increasing awareness pertaining to the spread of infections within healthcare settings and measures for prevention
• The competitive environment is marked by companies adopting sustainability strategies such as geographical expansion and mergers and acquisitions resulting in significant growth in their market share

Infection Control Market Report Scope

Report Attribute	Details
Market size value in 2023	USD 227.7 billion
Revenue forecast in 2030	USD 359.6 billion
Growth rate	CAGR of 6.7% from 2023 to 2030
Base year for estimation	2022
Historical data	2018 – 2021
Forecast period	2023 – 2030

List of Key Players of Infection Control Market

• 3M
• Belimed AG
• O&M Halyard or its affiliates.
• Getinge Group
• ASP
• MATACHANA
• Sterigenics U.S., LLC – A Sotera Health company
• MMM Group
• Cantel Medical Corp.
• STERIS plc.
• Midmark Corporation.
• Medivators Inc.
• W&H 

Access Press Release of Infection Control Market @ https://www.grandviewresearch.com/press-release/global-infection-control-market

Healthcare Customer Data Platform Market Segmented On The Basis Of Component, Deployment Mode, Organization Size, Application, Region And Forecast To 2028: Grand View Research Inc.

San Francisco, 29 Aug 2023: The Report Healthcare Customer Data Platform Market Size, Share & Trends Analysis Report By Component (Software, Services), By Deployment Mode (On-premise, Cloud-based), By Organization Size, By Application, By Region, And Segment Forecasts, 2021 – 2028

The global healthcare customer data platform market size is expected to reach USD 1.6 billion by 2028, based on a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 27.2% from 2021 to 2028. Due to the ongoing COVID-19 pandemic, patient needs and customer behavior patterns have changed and this trend is likely to continue until the pandemic is completely contained. The companies or brands require a structured approach to deal with the changing industry trends. The Customer Data Platform (CDP) systems have the potential to offer help in healthcare operations. Understanding patient preferences through predictive analytics is crucial for healthcare organizations. CDPs are now offering COVID-19 impact strategies to understand insights related to patient preferences.

CDPs can improve compliance with information privacy regulations such as the General Data Protection Regulation (EU) (GDPR) and the California Consumer Privacy Act (CCPA). These regulatory laws need companies to provide customers with the right to access their information. Meeting these regulatory requirements can be challenging for healthcare providers in case the patient data resides in different systems. CDPs create a unified view of each patient by capturing information from multiple channels, by linking data from those channels related to the same patient.

Traditional data management systems only collect summary information. However, CDPs have the ability to make completely linked customer information that is easily accessible to businesses. The correct use of CDP provides a foundation for marketing activities by connecting multiple information sources.

Access Research Report of Healthcare Customer Data Platform Market @ https://www.grandviewresearch.com/industry-analysis/healthcare-customer-data-platform-market-report

Healthcare Customer Data Platform Market Report Highlights

• Based on components, the software segment held a majority of the market share in terms of revenue in 2020 and is also expected to witness the fastest CAGR over the forecast period from 2021 to 2028
• Based on the deployment mode, the cloud-based deployment mode dominated the market in terms of revenue share in 2020 and is likely to grow at the fastest CAGR over the forecast period due to the quick access, higher flexibility, easier data back up, and lower handling costs
• Based on organization size, the large enterprises segment held a majority of the market share in 2020 owing to the growing demand for data platforms by the larger organizations
• Based on application, the predictive analytics segment dominated the market in terms of revenue share in 2020 as CDPs can turn big volumes of information into usable insights to guide business marketing decisions with predictive analytics
• In 2020, North America held a majority of the market share in terms of revenue due to the higher adoption of technology and growing development of IT infrastructure. Asia Pacific is expected to witness the fastest CAGR over the forecast period pertaining to the rising adoption of advanced healthcare IT solutions
• Since the number of vendors in the market is high, the vendors are likely to undertake mergers and acquisitions as strategic initiatives to stay viable in the market

Healthcare Customer Data Platform Market Report Scope

Report Attribute	Details
Market size value in 2021	USD 298.3 million
Revenue forecast in 2028	USD 1.6 billion
Growth rate	CAGR of 27.2% from 2021 to 2028
Base year for estimation	2020
Historical data	2016 – 2019
Forecast period	2021 – 2028

List of Key Players of Healthcare Customer Data Platform Market

• Microsoft
• Mercury Healthcare, Inc.
• Tealium, Inc.
• Innovaccer Inc.
• Adobe
• Treasure Data, Inc.
• Skypoint Cloud Inc.
• Solix Technologies, Inc.
• com, Inc.
• Reltio

Access Press Release of Healthcare Customer Data Platform Market @ https://www.grandviewresearch.com/press-release/global-healthcare-customer-data-platform-market

Monkeypox Vaccine And Treatment Market Segment Analysis By Product, Gender, Route Of Administration, End-Use, Region And Forecast Till 2030: Grand View Research Inc.

San Francisco, 25 Aug 2023: The Report Monkeypox Vaccine And Treatment Market Size, Share & Trends Analysis Report By Product (Vaccine, Drugs, Vaccinia Immune Globulin), By Gender, By Route Of Administration, By End-use, By Region, And Segment Forecasts, 2022 – 2030

The global monkeypox vaccine and treatment market size is expected to reach USD 184.79 million by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 10.16% from 2022 to 2030. The growing government initiatives for combating the monkeypox virus threat and a surge in awareness about the disease are the major factors driving the market. Moreover, an increase in R&D activities to develop vaccines and treatments is expected to fuel market growth.

The incidence rate of infection is higher in men as compared to women. According to the CDC’s data of August 2021, the monkeypox virus affected over 2,231 men of age 31 to 35 as compared to 11 women of age 31 to 35. The infection rate of the virus is more common in people between 20 to 50 years of age. Thus, the rising infection rates from the monkeypox virus are anticipated to fuel the demand for novel and effective treatment.

The increasing funding for boosting research activities and expanding manufacturing capacities of vaccine plants is likely to fuel market demand. For instance, in August 2022, the U.S. Department of Health and Human Services announced a funding of USD 11 million for providing support to fill and finish the manufacturing of JYNNEOS vaccine approved for preventing monkeypox and smallpox at GRAM, Michigan. This funding will assist GRAM to purchase extra equipment for JYNNEOS production.

Moreover, in July 2022, the pandemic institute awarded funding of around USD 580,049 to Liverpool researchers for managing the global threat of monkeypox. The funding is awarded for promoting research activities for understanding the stigma around the disease and developing new treatment regimens.

Furthermore, various strategic initiatives undertaken by the leading market players to strengthen their portfolio and market footprint are expected to facilitate market expansion. For instance, in August 2022, Bavarian Nordic A/S announced an agreement with Pan American Health Organization to boost equitable access to the Bavarian Nordic A/S monkeypox vaccine for countries in the Caribbean and Latin America. The vaccine delivery is likely to commence in the month of September.

In addition, in May 2022, SIGA Technologies, Inc. announced that its IV formulation TPOXX (tecovirimat) received U.S. FDA approval for the treatment of smallpox. The intravenous formulation is an alternative for patients who cannot swallow the oral formulation of the TPOXX. The IV formulation of TPOXX is also being used to manage the symptoms of monkeypox in the U.S.

However, the chances of side effects from the vaccine may hinder the market growth in the coming years. Some of the common side effects associated with the monkeypox vaccine include induration, muscle pain, swelling, nausea, and itching, among others.

Access Research Report of Monkeypox Vaccine And Treatment Market @ https://www.grandviewresearch.com/industry-analysis/monkeypox-vaccine-treatment-market-report

Monkeypox Vaccine And Treatment Market Report Highlights

• Based on product, the drugs segment held the largest share in 2022 owing to ongoing product approvals and increasing demand for antiviral drugs for the treatment
• The male segment accounted for the largest share in 2022 due to the higher prevalence of infections among men
• By route of administration, the oral segment dominated the market in 2022 due to the increased demand for oral antiviral drugs for the treatment of monkeypox disease
• The hospitals segment was the largest segment in 2022. The specialty clinics segment is anticipated to register the fastest growth rate throughout the forecast period
• Asia Pacific is expected to exhibit the fastest growth rate over the forecast period due to the increased risk of monkeypox infections and increasing awareness about vaccination

Monkeypox Vaccine And Treatment Market Report Scope

Report Attribute	Details
Market size value in 2023	USD 200.23 million
Revenue forecast in 2030	USD 184.79 million
Growth rate	CAGR of 10.16% from 2022 to 2030
Base year for estimation	2022
Historical data	2022 – 2030
Forecast period	2022 – 2030

List of Key Players of Monkeypox Vaccine And Treatment Market

• Bavarian Nordic
• SIGA Technologies
• Chimerix
• EMERGENT
• Gilead Sciences, Inc.

Access Press Release of Monkeypox Vaccine And Treatment Market @ https://www.grandviewresearch.com/press-release/global-monkeypox-vaccine-treatment-market

Synthetic Small Molecule API Market In-Depth Research On Basis By Manufacturer, Application, Region And Forecast To 2030: Grand View Research Inc.

San Francisco, 24 Aug 2023: The Report Synthetic Small Molecule API Market Size, Share & Trends Analysis Report By Manufacturer (In-house, Outsourced), By Application (Cardiology, Oncology), By Region, And Segment Forecasts, 2022 – 2030

The global synthetic small molecule API market size is expected to reach USD 217.17 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 5.73% from 2022 to 2030. This can be attributed to the increasing demand for pharmaceuticals and new small molecule-based drugs globally. Moreover, small molecules API offers versatility between dosage forms and has an easier means of purification, which makes it more acceptable and increases the demand.

There is an increasing dominance of synthetic drugs in the pharmaceutical industry, which is expected to propel the requirement of raw materials such as small molecule APIs for production. Moreover, technological advancements related to the enhancement of existing products are expected to provide new opportunities for small molecule therapeutics. For instance, in March 2022, Evonik launched the new EUDRATECSoluFlow technology that enhances the solubility of oral small molecules.

The market is driven by positive government support for the production of APIs in various regions, particularly in Asia, where the majority of API manufacturers are dependent on the supply of API for the production of synthetic small molecule APIs. There has been an increasing focus on outsourcing activities for API production. For instance, in April 2020, for managing COVID-19, Wavelength Pharmaceuticals expanded the supply of key drug ingredients for certain pharmaceutical products needed to manage respiratory critical care patients and launched API CDMO services. Emerging markets such as China, India, and Southeast Asia represent significant opportunities for growth.

The investment in new and complex technologies is relatively low for Asian manufacturers as they are more focused on less complex molecules that can be produced in bulk. Thus, the investment in high-yielding, low-cost technologies is an alternative for manufacturers in other developed regions such as Europe and North America to avoid competitive pressure.

Key players operating in the market are focusing on collaboration for the production of potent API products. For instance, in August 2021, Almac Sciences signed an agreement with Pila Pharma for the production of the API XEN-D0501, a highly potent and selective small molecule TRPV1 antagonist. Moreover, CDMOs are constantly evolving by expanding their capacities to meet the heightened demand for synthetic drugs. For instance, in April 2022, AGC Inc. announced the expansion of its Spanish facility by 7500 m² for synthetic pharmaceutical production, which is expected to enhance the demand for synthetic small molecule active pharmaceutical ingredients in the region.

Access Research Report of Synthetic Small Molecule API Market @ https://www.grandviewresearch.com/industry-analysis/synthetic-small-molecule-api-market-report

Synthetic Small Molecule API Market Report Highlights

• The growth of the overall market is attributed to the increasing production of pharmaceuticals with the increased demand for raw material
• The API market is witnessing a key shift with the rise in the preference for CDMOs for the production of synthetic small molecule active pharmaceutical ingredients in bulk
• By manufacturer, the outsourced segment is expected to witness lucrative growth over the forecast period owing to a dependency of small and mid-sized companies on outsourcing for commercial production
• The cardiology appolication segment dominated the market in 2021. This is attributed to the increasing prevalence of target diseases
• North America dominated the market in 2021 due to the presence of key players and rising support from the government for enhancing the API manufacturing capacity of the region

Synthetic Small Molecule API Market Report Scope

Report Attribute	Details
Market size value in 2022	USD 139.05 billion
Revenue forecast in 2030	USD 217.17 billion
Growth rate	CAGR of 5.73% from 2022 to 2030
Base year for estimation	2021
Historical data	2018 – 2020
Forecast period	2022 – 2030

List of Key Players of Synthetic Small Molecule API Market

• Bristol-Myers Squibb Company
• Cipla, Inc.
• Boehringer Ingelheim International GmbH
• Merck & Co., Inc.
• AbbVie, Inc.
• Aurobindo Pharma
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Albemarle Corporation
• Viatris Inc.
• Reddy’s Laboratories Ltd.

Access Press Release of Synthetic Small Molecule API Market @ https://www.grandviewresearch.com/press-release/global-synthetic-small-molecule-api-market

Transthyretin Amyloidosis Treatment Market Segment Analysis By Type, Therapy, Disease Type, Distribution Channel, Region And Forecast Till 2030: Grand View Research Inc.

San Francisco, 24 Aug 2023: The Report Transthyretin Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Type (ATTR-PN, ATTR-CM), By Therapy, By Disease Type, By Distribution Channel, By Region, And Segment Forecasts, 2022 – 2030

The global transthyretin amyloidosis treatment market size is expected to reach USD 9.17 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 7.6% from 2022 to 2030. The transthyretin amyloidosis treatment market is mainly driven by the presence of supportive reimbursement programs and the growing African American population. The increasing African American population acted as a catalyst for the industry growth throughout the period owing to the high susceptibility to ATTR amyloidosis. The Val122Ile is the most prevalent mutation worldwide that leads to cardiomyopathy among the population specific to aged 65 years and above. Furthermore, this Val122Ile mutation is present in 3% to 4% of the African American population worldwide.

An increase in research activities for the development of novel diagnostic techniques and multidisciplinary therapeutic approaches is expected to lead to an increased survival rate and a more favorable prognosis of transthyretin amyloidosis. For instance, in November 2019, the Amyloidosis Research Consortium developed a disease-specific patient-reported outcome (PRO) tool to understand and measure the impact of transthyretin amyloidosis from the patient perspective. An introduction of such a tool will boost the research in developing a new target-specific drug by understanding disease complexity and patients’ need, thereby widening the opportunity in the transthyretin amyloidosis treatment market.

Strategic initiatives undertaken by major players such as creating awareness regarding the target conditions such as ATTR and the long-term benefits of available therapies are expected to fuel industry growth. For instance, in 2019, Pfizer, Inc., in collaboration with the World Heart Federation, started the “Heart Hero” campaign. Under this campaign, Pfizer, Inc. provides educational information and resources related to ATTR-CM to patients and physicians. Such campaigns are expected to boost the early diagnosis of the disease and increase the treatment rate over time.

The movement undertaken by key players to provide free-of-cost medicine under their CSR activities is also projected to fuel market growth. For instance, the Pfizer Patient Assistance Program provides Pfizer medicines such as VYNDAMAX free of cost to eligible patients. People diagnosed with amyloidosis can take advantage of such programs by enrolling at the Vandalink platform. Such programs are expected to encourage physicians to prescribe this drug to a patient as drug therapy in transthyretin amyloidosis patients.

Access Research Report of Transthyretin Amyloidosis Treatment Market @ https://www.grandviewresearch.com/industry-analysis/transthyretin-amyloidosis-treatment-market-report

Transthyretin Amyloidosis Treatment Market Report Highlights

• By type, the ATTR-CM accounted for a leading share in 2021 owing to the high prevalence of the disease and the rising geriatric population. The ATTR-PN is expected to exhibit the fastest growth rate throughout the forecast period. The segment growth is attributed to the presence of a strong pipeline
• By therapy, the targeted therapy segment grabbed a dominant share in 2021 owing to the worldwide approval of the therapies and the growing prescription rate for the treatment of ATTR-CM
• By disease type, the hereditary transthyretin amyloidosis segment dominated the market in 2021 owing to growing strategic alliances among various pharmaceutical companies aiming toward drug development along with growing pipeline drugs
• By distribution channel, the hospital pharmacies captured the largest share in 2021 as most of the hospitals are working toward the diagnosis, research, and treatment of transthyretin amyloidosis
• North America region held the largest share in 2021 owing to the increasing novel drug prescription, proper reimbursement policies, and higher treatment rates in the region
• The MEA region is expected to exhibit the fastest growth rate throughout the forecast period. The segment growth is attributed to the increasing incidence of ATTR amyloidosis 

Transthyretin Amyloidosis Treatment Market Report Scope 

Report Attribute	Details
Market size value in 2022	USD 5.11 billion
Revenue forecast in 2030	USD 9.17 billion
Growth rate	CAGR of 7.6% from 2022 to 2030
Base year for estimation	2021
Historical data	2018 – 2020
Forecast period	2022 – 2030

List of Key Players of the Transthyretin Amyloidosis Treatment Market

• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• Ionis Pharmaceuticals, Inc.
• Alnylam Pharmaceuticals, Inc.
• BridgeBio Pharma, Inc.
• Bristol-Myers Squibb Company
• Acrotech Biopharma
• AstraZeneca
• Astellas Pharma, Inc.
• Prothena
• SOM Biotech

Access Press Release of Transthyretin Amyloidosis Treatment Market @ https://www.grandviewresearch.com/press-release/global-transthyretin-amyloidosis-treatment-market

Healthcare Third-party Logistics Market Segment Analysis By Industry, Supply Chain, Service Type, Region And Forecast Till 2030: Grand View Research Inc.

San Francisco, 23 Aug 2023: The Report Healthcare Third-party Logistics Market Size, Share & Trends Analysis Report By Industry (Biopharmaceutical, Pharmaceutical, Medical Device), By Supply Chain, By Service Type, By Region, And Segment Forecasts, 2022 – 2030

The global healthcare third-party logistics market size is expected to reach USD 368.2 million by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to expand at a CAGR of 7.6% from 2022 to 2030. A few factors driving the growth of this market are technological advancements that help in developing new technologies to engage with consumers, help in the reduction of operational costs, and help in expanding the business into emerging countries and new markets.

The COVID-19 pandemic significantly impacted the supply chain market and the way it is managed. However, the third-party logistics industry showed growth amid this pandemic. This is because they matched the rising demand with reliable manufacturers worldwide. In addition to the basic storage and transportation services during the pandemic, they also provided procurement assistance to relatively small retailers. For instance, in September 2021, FedEx Corp. subsidiary FedEx Express delivered COVID-19 swab kits and personal protective equipment on 15 pallets to Jakarta, Indonesia.

There has also been an increase in healthcare companies partnering with third-party logistics providers to operate in a growing and changing set of regulatory requirements that vary by product classification, region, and state. Healthcare third-party logistics (3PL) help in complying with these regulations without disturbing the time duration, efficiency, and cost-effectiveness. They also help in streamlining and simplifying the regulatory compliance process.

Access Research Report of Healthcare Third-party Logistics Market @ https://www.grandviewresearch.com/industry-analysis/healthcare-third-party-logistics-market-report

Healthcare Third-party Logistics Market Report Highlights

• The industry segment is segmented into biopharmaceutical, pharmaceutical, and medical devices. And the biopharmaceutical segment accounted for the largest revenue share of 62.6% in 2021
• The cold chain logistics segment is anticipated to advance at the fastest CAGR of 10.5% during the forecast period. This is due to the rising demand for biologics which is a novel class of pharmaceutical
• North America dominated the global market with the largest revenue share of 42.0% in 2021 owing to the presence of a large number of players as well as growth in pharmaceutical and biopharmaceutical exports and imports
• For instance, in April 2021, FedEx Corp. subsidiary FedEx Express supplied 1,000 oxygen cylinders and 1,800 pounds of personal protective equipment and medicines to India

Healthcare Third-party Logistics Market Report Scope

Report Attribute	Details
Market size value in 2022	USD 204.8 million
Revenue forecast in 2030	USD 368.2 million
Growth rate	CAGR of 7.6% from 2022 to 2030
Base year for estimation	2021
Historical data	2018 – 2020
Forecast period	2022 – 2030

List of Key Players in the Healthcare Third-party Logistics (3PL) Market

• Cardinal Health
• DHL International GmbH
• Agility
• SF Express
• Kinesis Medical B.V.
• United Parcel Service of America, Inc.
• Barrett Distribution
• AmerisourceBergen Corporation
• DB Schenker
• KUEHNE + NAGEL
• Kerry Logistics Network Ltd.
• Freight Logistics Solutions.

Access Press Release of Healthcare Third-party Logistics Market @ https://www.grandviewresearch.com/press-release/global-healthcare-third-party-logistics-market

Dental Inlays & Onlays Market Outlook On The Basis Of Material, Type, Region And Forecast To 2030: Grand View Research Inc.

San Francisco, 23 Aug 2023: The Report Dental Inlays & Onlays Market Size, Share & Trends Analysis Report By Material (Porcelain, Zirconia, Gold, Composite), By Type (Direct, Indirect), By Region, And Segment Forecasts, 2022 – 2030

The global dental inlays and onlays market size is expected to reach USD 7.6 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 11.0% from 2022 to 2030. The increase in the number of dental practices, the increase in the prevalence of dental diseases, the surge in public awareness regarding dental inlays and onlays procedures, and the surge in the demand for cosmetic dentistry among the young population are the major factors that drive the market. In addition, extensive use of porcelain materials in dental restoration procedures, advancements in the techniques used in dental practices, and improvements in dental inlays and onlays materials further boost the growth of the market.

The COVID-19 epidemic had disturbed several dental inlays and onlays procedures due to the strict restrictions enforced by the government. The epidemic has resulted in the enclosure of dental care facilities and a decrease in the number of patient visits to dental clinics. Also, COVID-19 resulted in tele consultancy as dental professionals were not going to offices for practice during the pandemic period. However, in 2021, there was no major impact on the market as dental offices were reopened in many countries and the number of dental inlays and onlays procedures also increased.

An increase in public preference for minimally invasive dental restoration treatments, a rise in the number of dental practitioners, a surge in R&D activities, new dental inlays and onlays material launches, and a rise in healthcare expenditure foster the growth of the market. Moreover, dental inlays and onlays provide advantages such as strong and durable nature, enhanced physical properties to conventional composite filling, and minimal post-operative sensitivity. Furthermore, strong medical infrastructure and well-established reimbursement policies in developed countries drive the market.

Access Research Report of Dental Inlays & Onlays Market @ https://www.grandviewresearch.com/industry-analysis/dental-inlays-onlays-market-report

Dental Inlays & Onlays Market Report Highlights

• Porcelain emerged as the largest material segment in 2021 with over 30.0% share due to a rapid surge in the demand for porcelain dental inlays and onlays in dental practices
• By type, the direct segment accounted for the largest market share in 2021 and is expected to witness the highest growth over the forecast period due to the rise in the patient preference for direct-type dental inlays and onlays
• North America captured the largest share in 2021 owing to rapid advancement in the restorative dentistry sector by key players and growing R&D activities in dentistry 

Dental Inlays & Onlays Market Report Scope 

Report Attribute	Details
Market size value in 2022	USD 3.3 billion
Revenue forecast in 2030	USD 7.6 billion
Growth rate	CAGR of 11.0% from 2022 to 2030
Base year for estimation	2021
Historic data	2018 – 2020
Forecast period	2022 – 2030

List of Key Players in the Dental Inlays & Onlays Market

• 3M Company
• Glidewell Laboratories
• Smile Brands
• Institut Straumann AG
• Ivoclar Vivadent AG
• COLTENE Holding AG
• Dentsply Sirona
• Aspen Dental
• National Dentex Corporation
• DenMat

Access Press Release of Dental Inlays & Onlays Market @ https://www.grandviewresearch.com/press-release/global-dental-inlays-onlays-market

Bovine Artificial Insemination Market Segmented On The Basis Of Solution, Distribution Channel, Sector, Region And Forecast 2030: Grand View Research Inc.

San Francisco, 21 Aug 2023: The Report Bovine Artificial Insemination Market Size, Share & Trends Analysis Report By Solutions (Equipment & Consumables, Semen, Services), By Sector (Meat, Dairy), By Distribution Channel (Private, Public), By Region, And Segment Forecasts, 2023 – 2030

The global bovine artificial insemination market size is expected to reach USD 4.54 billion by 2030, registering a CAGR of 6.17% over the forecast period, according to a new report by Grand View Research, Inc. The market is driven by increasing demand for high-quality beef and dairy products, a focus on improving the genetic traits of bovines, as well as advancements in breeding technology. Artificial insemination facilitates animal owners to select the best sires for their cows, resulting in offspring with desirable traits such as increased milk production or meat yield.

As per OECD 2020-29 estimates, about 80% of the world’s milk production comprises cow milk. By 2029, India and Pakistan are projected to contribute to over 30% of the worldwide milk production. This is expected to propel the demand for bovine AI solutions to ensure efficient breeding programs. The COVID-19 pandemic limited access to artificial insemination solutions such as equipment, semen, and services. This led to dampened growth and reduced sales across the market. However, the market has recovered gradually since then, owing to unchanged underlying drivers.

For instance, advances in breeding technology have made artificial insemination a more efficient and affordable option for farmers. Semen can be collected from top-performing bulls and stored for use later, allowing farmers to access superior genetics without having to purchase expensive bulls or maintain them on their farms. Governments in many countries are also supporting the use of artificial insemination as a means of improving livestock productivity and reducing the environmental impact of animal agriculture.

Initiatives to ensure the highest possible genetic progress in bovines, such as cattle and buffaloes, are expected to fuel market growth. In December 2020, Evolution, VikingGenetics, and Masterrind came together to form a dairy and beef genetic cooperative – Arcowin. It is aimed at ensuring the highest possible and the most sustainable genetic progress. The leading stakeholders: Evolution, VikingGenetics, and Masterrind, are key cooperatives within cattle breeding, with strong bases in Finland, France, Germany, Denmark, and Sweden. The formation of Arcowin enabled the 3 organizations to use their genetic resources and investments better.

Access Research Report of Bovine Artificial Insemination Market @ https://www.grandviewresearch.com/industry-analysis/bovine-artificial-insemination-market-report

Bovine Artificial Insemination Market Report Highlights

• By solutions, the services segment dominated the market in 2022 with a share of around 39.0%. The semen segment, on the other hand, is projected to expand at the fastest CAGR of 6.88% through 2030
• The increasing awareness and uptake of bovine artificial insemination services is a key factor attributing to the high share of the segment
• AI Services (NI) Ltd., for instance, offers artificial insemination services to livestock producers across Northern Ireland. A key part of its business comes from the sale of high-quality semen to service users and D.I.Y. operators
• In terms of the distribution channel, private channels accounted for a larger share of the market in 2022 and are also expected to expand at the fastest rate of 6.73% during the forecast period
• The dairy segment dominated the market in 2022 in terms of sector and is also anticipated to advance at the fastest CAGR of 6.6% from 2023 to 2030
• In 2022, North America accounted for the highest share of about 30% of the market, in terms of region
• Asia Pacific is anticipated to grow at the fastest rate of over 7% during the projection period, owing to the thriving dairy and beef sector in key regional markets

Bovine Artificial Insemination Market Report Scope

Report Attribute	Details
Market size value in 2023	USD 2.98 billion
Revenue forecast in 2030	USD 4.54 billion
Growth rate	CAGR of 6.17% from 2023 to 2030
Base year for estimation	2022
Actual estimates/Historical data	2018 – 2021
Forecast period	2023 – 2030

 List of Key Players in the Bovine Artificial Insemination Market

• Genus plc
• IMV Technologies
• SEMEX
• Jorgensen Laboratories
• URUS Group
• STgenetics
• National Dairy Development Board
• Munster Bovine 
• World Wide Sires, Ltd.
• Cogent Breeding Ltd.

Access Press Release of Bovine Artificial Insemination Market @ https://www.grandviewresearch.com/press-release/global-bovine-artificial-insemination-market

Uterine Fibroid Treatment Drugs Market Segment Analysis By Drug Class, Type, End-User, Region And Forecast Till 2030: Grand View Research Inc.

San Francisco, 17 Aug 2023: The Report Uterine Fibroid Treatment Drugs Market Size, Share & Trends Analysis Report By Drug Class (GnRH Agonists, GnRH Antagonists), By Type (Submucosal Fibroids, Intramural Fibroids), By End-user, And Segment Forecasts, 2023 – 2030

The global uterine fibroid treatment drugs market size is expected to reach USD 3.91 billion by 2030, expanding at a CAGR of 10.2% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the rising prevalence of Uterine Fibroids (UF) and the increased effectiveness of novel drugs in reducing heavy menstrual bleeding in women. According to an article published on IntechOpen, heavy menstrual bleeding is a common symptom of uterine fibroids affecting approximately 1.4 million women per year. In addition, nearly 60% of women report that symptoms impede physical activity and affect their quality of life. Moreover, 24% of women reported that symptoms prevent them from performing to their full ability at work.

Therefore, the rising demand for novel drugs with an advanced mechanism of action, higher clinical efficacy & lesser side effects is expected to drive the market. In addition, rising funding for research activities is expected to boost market growth. For instance, the Society for Women’s Health Research (SWHR) endorsed the updated & re-introduced Stephanie Tubbs Jones Uterine Fibroid Research & Education Act of 2021. The act is designed to advance funding for research and enhance education regarding the condition. The recent approval of multiple Gonadotropin-releasing Hormone (GnRH) antagonists for the treatment of heavy bleeding associated with fibroids will also drive the market. For instance, in May 2020, the U.S. FDA approved Oriahnn for the treatment of uterine fibroids.

It became the first oral medication approved for the treatment of heavy bleeding in pre-menopausal women. The drug has a treatment duration of 24 months and is available at a retail price of USD 1,100 for 56 tablets. Furthermore, key players are focusing on new launches, mergers & acquisitions, expansion, and partnerships for gaining higher market shares. For instance, in June 2022, Kissei Pharmaceuticals announced the initiation of Phase III trials for its drug, linzagolix, for the treatment of uterine fibroids, in Japan. The drug has already been approved by EMA under the brand name Yselty in Europe. The original developer, ObsEva, sold the regional rights for this drug to Theramex in Feb 2022. The deal grants Theramex the rights to sell this drug in Europe, Brazil, and Australia.

Access Research Report of Uterine Fibroid Treatment Drugs Market @ https://www.grandviewresearch.com/industry-analysis/uterine-fibroid-treatment-drugs-market-report

Uterine Fibroid Treatment Drugs Market Report Highlights

• The GnRH antagonists segment is expected to register the fastest growth rate over the forecast period
• The recent approval of multiple drugs, such as Oriahnn in May 2020 in the U.S., Myfembree in May 2021 in the U.S., and Yselty in June 2022 in Europe, is expected to drive market growth
• The submucosal fibroids segment held the majority of the share of the UF drugs market in 2022
• Retail pharmacies dominated the market in 2022 on account of the ease of availability of medications in these pharmacies
• North America held the largest share of the global market in 2022 due to various factors, such as the presence of major players, the high prevalence of the health condition, and increasing awareness among patients regarding the availability of medications

Uterine Fibroid Treatment Drugs Market Report Scope

Report Attribute	Details
Market size value in 2023	USD 2.0 billion
Revenue forecast in 2030	USD 3.91 billion
Growth rate	CAGR of 10.2% from 2023 to 2030
Base year for estimation	2022
Historical data	2018 – 2021
Forecast period	2023 – 2030

List of Key Players in Uterine Fibroid Treatment Drugs Market

• Myovant Sciences GmbH
• Pfizer Inc.
• Abbvie, Inc.
• Ferring B.V.
• AstraZeneca
• Bayer AG
• Amring Pharmaceuticals Inc.
• Watson Pharma, Inc.

Access Press Release of Uterine Fibroid Treatment Drugs Market @ https://www.grandviewresearch.com/press-release/global-uterine-fibroid-treatment-drugs-market

Dental Services Market Outlook On The Basis Of Type, End-Use, Region And Forecast From 2023 to 2030: Grand View Research Inc.

San Francisco, 1 June 2023: The Report Dental Services Market Size, Share & Trends Analysis Report By Type (Dental Implants, Orthodontics, Periodontics, Endodontics), By End-use (Hospitals, Dental Clinics), By Region, And Segment Forecasts, 2023 – 2030

The global dental services market size is expected to reach USD 610.4 billion by 2030, based on a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 4.5% from 2023 to 2030. The marketing efforts to commercialize dental practices including education camps and online campaigns are contributing to the adoption of dental services. Rapid urbanization around the world, constant economic growth, and the rising disposable income of people have contributed to the relatively steady growth of the market. In addition, per capita, consumption expendituree on healthcare services is likely to significantly increase in the coming years.

The market for dental services was severely impacted due to the COVID-19 pandemic as the clinics were closed due to the imposed social distancing. In March 2020, the American Dental Association (ADA) issued guidelines to postpone elective dental procedures. Only emergency procedures were allowed to carry out during the early phase of the pandemic.

In April 2021, Mills Administration, in partnership with Northeast Delta Dental launched the Maine Veterans’ Dental Network. It was launched officially in May 2021 and provides services to Maines’s veterans who were not able to afford it. In July 2021, Geyer Dental Group updated their Dental Crown Repair/Cap Fitting Restorative Dentistry service for the people in Greater St. Louis. The practice offers periodontal, cosmetic, and restorative dentistry.

Access Research Report of Dental Services Market @ https://www.grandviewresearch.com/industry-analysis/dental-services-market-report

Dental Services Market Report Highlights

• Based on type, the dental implants segment held the dominant revenue share in 2022. as these implants provide patients with functional options for teeth replacement procedures. With the R&D in this field, dental implants are available with better biomaterials, improved designs, and surface modifications
• The cosmetic dentistry type segment is likely to witness the fastest CAGR from 2023 to 2030 owing to the rising adoption of teeth appearance improvement procedures, such as teeth whitening, crowns, inlays and onlays, and veneers
• Based on end-use, the dental clinic segment held the largest share in terms of revenue in 2022 and is expected to witness the fastest growth over the forecast period. The majority of patients visit private practice dental clinics due to the availability of specialists, cost efficiency, and advanced technology
• In 2022, North America dominated the market in terms of revenue owing to factors including the presence of independent dental clinics, growing R&D activities in dentistry, and rising disposable income. The increasing government funding for dental programs is likely to contribute to the growth
• The Asia Pacific region is anticipated to witness the fastest CAGR from 2023 to 2030 due to the growing number of dental clinics and rising awareness about oral care. The healthcare infrastructure in the Asia Pacific is expanding with advanced technology and equipment

List of Key Players in the Dental Services Market

• Aspen Dental Management Inc.
• InterDent, Inc.
• National Health Service England
• The British United Provident Association Limited
• Apollo White Dental
• Abano Healthcare Group Limited
• Coast Dental
• Dental Service Group
• Axis Dental
• Integrated Dental Holdings
• Pacific Dental Service
• Gentle Dental of New England

Access Press Release of Dental Services Market @ https://www.grandviewresearch.com/press-release/global-dental-services-market